FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression
- PMID: 30074276
- DOI: 10.1002/mc.22884
FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression
Abstract
Although genetic amplification and overexpression of the fibroblast growth factor 19 (FGF19) gene are found in human breast cancer, mechanisms that contribute to such functional alterations remain elusive. We report here that high expression of FGF19 is associated with the aggressive malignant behavior and poor survival outcome of breast cancer patients. FGF19 is particularly highly expressed in luminal molecular subtype of breast tumors and its expression levels are positively associated with its secretion levels from breast cancer cells. Genetic knockout of FGF19 significantly induces repression of breast tumor progression and metastasis in either an orthotopic mouse model of breast cancer or an experimental metastasis model. The FGF19 specific receptor, FGFR4, can be activated and subsequently upregulate AKT signaling in breast cancer cell upon FGF19, which is critical for oncogenic role of FGF19. Inactivation of FGFR4 by its inhibitor BLU9931 significantly attenuates FGF19-induced tumor-promoting activity, suggesting interruption of FGFR4 function is sufficient to affect FGF19-driven breast cancer. Overall, these insights support the idea that targeting FGFR4 in breast cancer cells overexpressing FGF19 may represent an effective strategy to suppress cancer development, progression, and metastasis.
Keywords: AKT; BLU9931; FGF19; FGFR4; breast cancer; invasion and metastasis.
© 2018 Wiley Periodicals, Inc.
Similar articles
-
Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.Oncotarget. 2016 Sep 6;7(36):57633-57650. doi: 10.18632/oncotarget.9328. Oncotarget. 2016. PMID: 27192118 Free PMC article.
-
Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4.Hepatology. 2020 May;71(5):1712-1731. doi: 10.1002/hep.30951. Epub 2020 Feb 10. Hepatology. 2020. PMID: 31529503
-
Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer.Oncol Rep. 2015 Nov;34(5):2683-91. doi: 10.3892/or.2015.4212. Epub 2015 Aug 20. Oncol Rep. 2015. PMID: 26323668
-
Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.Curr Cancer Drug Targets. 2019;19(1):17-25. doi: 10.2174/1568009618666180319091731. Curr Cancer Drug Targets. 2019. PMID: 29557750 Review.
-
Making way for suppressing the FGF19/FGFR4 axis in cancer.Future Med Chem. 2018 Oct;10(20):2457-2470. doi: 10.4155/fmc-2018-0099. Epub 2018 Oct 16. Future Med Chem. 2018. PMID: 30325210 Review.
Cited by
-
Novel Regulatory Factors and Small-Molecule Inhibitors of FGFR4 in Cancer.Front Pharmacol. 2021 Apr 26;12:633453. doi: 10.3389/fphar.2021.633453. eCollection 2021. Front Pharmacol. 2021. PMID: 33981224 Free PMC article. Review.
-
Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies.Cells. 2019 Jan 9;8(1):31. doi: 10.3390/cells8010031. Cells. 2019. PMID: 30634399 Free PMC article. Review.
-
TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment.Oncogene. 2020 Jan;39(1):64-78. doi: 10.1038/s41388-019-0959-3. Epub 2019 Aug 28. Oncogene. 2020. PMID: 31462709 Free PMC article.
-
Novel Abs targeting the N-terminus of fibroblast growth factor 19 inhibit hepatocellular carcinoma growth without bile-acid-related side-effects.Cancer Sci. 2020 May;111(5):1750-1760. doi: 10.1111/cas.14353. Epub 2020 Mar 20. Cancer Sci. 2020. PMID: 32061104 Free PMC article.
-
Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer.Cancer Res Commun. 2023 Apr 19;3(4):659-671. doi: 10.1158/2767-9764.CRC-22-0289. eCollection 2023 Apr. Cancer Res Commun. 2023. PMID: 37089864 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous